- Home
- PMVP vs MIST Comparison
PMVP vs MIST Comparison
Compare PMVP & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- MIST
- Stock Information
- Founded
- PMVP 2013
- MIST 2003
- Country
- PMVP United States
- MIST Canada
- Employees
- PMVP N/A
- MIST N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- MIST Health Care
- Exchange
- PMVP Nasdaq
- MIST Nasdaq
- Market Cap
- PMVP 85.5M
- MIST 100.3M
- IPO Year
- PMVP 2020
- MIST N/A
- Fundamental
- Price
- PMVP $1.51
- MIST $1.81
- Analyst Decision
- PMVP Strong Buy
- MIST Strong Buy
- Analyst Count
- PMVP 4
- MIST 3
- Target Price
- PMVP $5.75
- MIST $13.00
- AVG Volume (30 Days)
- PMVP 196.4K
- MIST 372.6K
- Earning Date
- PMVP 11-07-2024
- MIST 11-12-2024
- Dividend Yield
- PMVP N/A
- MIST N/A
- EPS Growth
- PMVP N/A
- MIST N/A
- EPS
- PMVP N/A
- MIST N/A
- Revenue
- PMVP N/A
- MIST N/A
- Revenue This Year
- PMVP N/A
- MIST N/A
- Revenue Next Year
- PMVP N/A
- MIST N/A
- P/E Ratio
- PMVP N/A
- MIST N/A
- Revenue Growth
- PMVP N/A
- MIST N/A
- 52 Week Low
- PMVP $1.40
- MIST $1.12
- 52 Week High
- PMVP $3.47
- MIST $2.93
- Technical
- Relative Strength Index (RSI)
- PMVP 38.59
- MIST 49.60
- Support Level
- PMVP $1.55
- MIST $1.76
- Resistance Level
- PMVP $1.61
- MIST $1.86
- Average True Range (ATR)
- PMVP 0.07
- MIST 0.10
- MACD
- PMVP -0.01
- MIST -0.02
- Stochastic Oscillator
- PMVP 18.18
- MIST 18.93
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).